Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free WINT Stock Alerts

Windtree Therapeutics (WINT) Competitors

Windtree Therapeutics logo
$0.0001 -0.01 (-99.17%)
As of 07/24/2026 01:32 PM Eastern
Compare

WINT vs. FLGC, BPTH, VIVS, CANF, and CMND

Should you buy Windtree Therapeutics stock or one of its competitors? MarketBeat compares Windtree Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Windtree Therapeutics include Flora Growth (FLGC), Bio-Path (BPTH), VivoSim Labs (VIVS), Can-Fite BioPharma (CANF), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry.

How does Windtree Therapeutics compare to Flora Growth?

Windtree Therapeutics (NASDAQ:WINT) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Windtree Therapeutics has higher earnings, but lower revenue than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Flora Growth$57.61M0.03-$15.91M-$32.49N/A

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Flora Growth Neutral

Windtree Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Flora Growth has a consensus price target of $30.00, suggesting a potential upside of 1,968.97%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts plainly believe Flora Growth is more favorable than Windtree Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Flora Growth
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Windtree Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Flora Growth -32.03%-64.02%-34.46%

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Flora Growth beats Windtree Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Windtree Therapeutics compare to Bio-Path?

Windtree Therapeutics (NASDAQ:WINT) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Bio-Path is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Bio-PathN/AN/A-$16.08M-$1.09N/A

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Windtree Therapeutics' return on equity of -207.34% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Bio-Path N/A -2,842.40%-337.48%

Windtree Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

In the previous week, Bio-Path had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Bio-Path Neutral

Summary

Windtree Therapeutics beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Windtree Therapeutics compare to VivoSim Labs?

VivoSim Labs (NASDAQ:VIVS) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

VivoSim Labs has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Windtree Therapeutics has lower revenue, but higher earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VivoSim Labs$130K11.25-$13.84M-$5.36N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

In the previous week, VivoSim Labs had 4 more articles in the media than Windtree Therapeutics. MarketBeat recorded 4 mentions for VivoSim Labs and 0 mentions for Windtree Therapeutics. VivoSim Labs' average media sentiment score of 1.12 beat Windtree Therapeutics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company Overall Sentiment
VivoSim Labs Positive
Windtree Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VivoSim Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Windtree Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Windtree Therapeutics' return on equity of -207.34% beat VivoSim Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
VivoSim Labs-10,567.17% -277.62% -153.77%
Windtree Therapeutics N/A -207.34%-50.19%

Summary

Windtree Therapeutics beats VivoSim Labs on 7 of the 13 factors compared between the two stocks.

How does Windtree Therapeutics compare to Can-Fite BioPharma?

Windtree Therapeutics (NASDAQ:WINT) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Windtree Therapeutics has higher earnings, but lower revenue than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Can-Fite BioPharma$405K5.16-$7.63M-$22.80N/A

Can-Fite BioPharma's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Can-Fite BioPharma N/A N/A N/A

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 1,279.31%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Windtree Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Can-Fite BioPharma Neutral

Windtree Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

Can-Fite BioPharma beats Windtree Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Windtree Therapeutics compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Clearmind Medicine's return on equity of -143.79% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -143.79% -88.51%
Windtree Therapeutics N/A -207.34%-50.19%

In the previous week, Clearmind Medicine had 4 more articles in the media than Windtree Therapeutics. MarketBeat recorded 4 mentions for Clearmind Medicine and 0 mentions for Windtree Therapeutics. Clearmind Medicine's average media sentiment score of 0.69 beat Windtree Therapeutics' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Positive
Windtree Therapeutics Neutral

Clearmind Medicine has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Clearmind Medicine is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$139.98N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Summary

Windtree Therapeutics beats Clearmind Medicine on 6 of the 10 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WINT vs. The Competition

Export
MetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$540K$3.67B$6.87B$12.26B
Dividend YieldN/A2.19%2.67%9.79%
P/E Ratio0.0021.2927.1123.64
Price / SalesN/A161.81496.7876.82
Price / CashN/A157.9050.5459.64
Price / Book0.007.8810.286.07
Net Income-$1.79M$23.86M$3.60B$331.99M
7 Day PerformanceN/A-3.82%-1.27%-0.63%
1 Month PerformanceN/A-2.61%-0.37%-2.00%
1 Year PerformanceN/A32.79%18.30%13.62%

Windtree Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WINT
Windtree Therapeutics
N/A$0.00
-99.2%		N/A-100.0%$540KN/AN/A30
FLGC
Flora Growth
N/A$2.18
-2.7%		$30.00
+1,276.1%		-93.8%$2.28M$57.61MN/A280
BPTH
Bio-Path
N/A$0.04
+22.0%		N/A-74.2%$2.15MN/AN/A10
VIVS
VivoSim Labs
0.9382 of 5 stars		$0.83
+3.2%		N/A-81.0%$2.11M$140KN/A20
CANF
Can-Fite BioPharma
1.7011 of 5 stars		$3.22
-1.2%		$44.00
+1,266.5%		-84.2%$2.11M$405KN/A8

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:WINT) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel